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with the inhibition of the metastatic potential of cancer cells,
following inhibition of ZEB transcription factors expression
and epithelial-to-mesenchymal transition. However, previous
studies performed in pancreatic adenocarcinoma revealed a
more complex picture challenging this canonical model. To
gain better insights into the role of miR-200 family members
in this disease, we analyzed the expression of miR-200a, miR-
200b, miR-200c, miR-141, miR-429, and miR-205, and ZEB1,
ZEB2, and CDH1 in pancreatic tumors and matching normal
adjacent parenchyma and patient-derived xenografts. We found
that miR-200a, miR-429, and miR-205 are frequently overex-
pressed in pancreatic tumors, whereas CDH1 is downregulated,
and ZEB1 and ZEB2 levels remain unchanged. Furthermore, we
measured a positive correlation between miR-200 family mem-
bers and CDH1 expression, and a negative correlation between
ZEB1 and miR-200c, miR-141, and miR-205 expression, respec-
tively. Interestingly, we identified significant changes in expres-
sion of epithelial-to-mesenchymal transition regulators and
miR-200 members in patient-derived xenografts. Lastly, func-
tional studies revealed that miR-141 and miR-429 inhibit the
tumorigenic potential of pancreatic cancer cells. Taken together,
this comprehensive analysis strongly suggests thatmiRNAs from
the miR-200 family, and in particular miR-429, may act as a tu-
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Pancreatic ductal adenocarcinoma (PDAC) cancer is the most com-
mon pancreatic neoplasm and is currently the third cause of can-
cer-related mortality in Western countries.1 PDAC is particularly
aggressive because it easily invades adjacent tissues and metastasizes
to distant organs.2 Moreover, PDAC is resistant to standard
chemotherapies.3 The most frequent genetic abnormalities in
PDAC generally follow a characteristic pattern whereKRAS oncogene
activation is an early event, with alterations in CDKN2A, TP53,
SMAD4, and BRCA2 accumulating in later stages.2Mo
This is an open access article under the CC BY-NC-Tumor progression andmetastases formation in carcinomas are asso-
ciated with a series of changes including epithelial-to-mesenchymal
transition (EMT) to increase cell motility and invasiveness.4,5 Down-
regulation of E-cadherin (CDH1) expression leading to loss of cell
adhesion is considered a key feature of EMT.5 Transcription factors
ZEB1 and ZEB2 directly inhibit E-cadherin expression and are often
upregulated in cancer cells.6 Other transcription factors that regulate
CDH1, such as Snail and Twist families, can be also upregulated.7
MicroRNAs (miRNAs) are a class of highly conserved, small non-
coding RNAs that regulate gene expression by targeting mRNAs for
cleavage or translational repression.8 The miR-200 family is
composed of fivemembers distributed in two clusters. The first cluster
is located in chromosome 1 and consists of miR-200b, miR-200a, and
miR-429. The second cluster is hosted by chromosome 12 and in-
cludes miR-200c and miR-141.9 In most tumors, miR-200 family
members, as well as miR-205, which does not belong to this family,
inhibit the expression of ZEB1 and ZEB2 transcription factors,
notably following binding to their UTR.10 This is relevant for the
maintenance of the epithelial integrity because it prevents EMT.11–14
Although several studies have reported the downexpression of miR-
200 family members in lung,15 colon,16 or breast tumors,11 upregula-
tion of miR-200 is upregulated in non-small-cell lung cancer.17
Furthermore, enforced miR-200 expression promotes metastaticlecular Therapy: Nucleic Acids Vol. 17 September 2019 ª 2019 491
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Expression Levels of miR-200 Family Members and ZEB1, ZEB2,
and CDH1 in Primary Tumors of PDAC
(A) Target genes expression was measured in duplicates by quantitative real-time
PCR in primary tumors and matching adjacent normal tissues. Results are repre-
sented as fold changes in gene expression. *p < 0.05; **p < 0.01; ***p < 0.001
(Wilcoxon test). (B) Expression of candidate microRNAs in microdissected ductal
cancer cells and pancreatic stromal cells. Ductal and stromal compartments were
microdissected in nine PDAC primary tumors as described in the Materials and
Methods. miR-200, miR-141, and miR-429 miRNAs were quantified by
quantitative real-time PCR in triplicates. Relative miRNA expression is expressed as
2(CtmiRNA-CtRNU48). Forty cycles were attributed when miRNA was undetectable.
Molecular Therapy: Nucleic Acidsspread in breast cancer models,18,19 but overexpression of miR-141 or
miR-429 has been associated with a suppressor gene function in
several tumor types.20–23
However, the picture is seemingly more complex for PDAC. miR-
200 family members are frequently overexpressed in precursor
lesions24 and PDAC,18,25 where they may act as oncogenes26 or as
suppressor genes.27 A complex crosstalk between miR-200 and
ZEBs has been suggested. Even though miR-200 family members
negatively regulate ZEBs, ZEB1 expression may result in the down-
regulation of miR-141 and miR-200c levels in pancreatic, colorectal,
and breast cancer cells.28 Recently, similar studies described ZEB1 as
a key factor in precursor lesions formation, but also in tumor inva-
sion and metastasis.29492 Molecular Therapy: Nucleic Acids Vol. 17 September 2019The goal of this study was to get better insights into the complex
crosstalk between miR-200 family members and EMT regulators, in
PDAC primary tumors and in experimental metastases derived
from patient-derived xenografts (PDXs). Moreover, the potential ef-
fect of miR-200 family members was explored in experimental models
of PDAC. Our results depict a specific pattern of deregulation of miR-
200 family members, as well as miR-205, in primary PDAC tumors.
This pattern of expression was positively correlated with CDH1
expression and negatively correlated with ZEB transcription factors
expression, respectively. Notably, miRNA and EMT regulators
expression remained stable during PDX dissemination in mice,
regardless of the site of metastasis, demonstrating the importance
of this network in PDAC carcinogenesis. Lastly, functional studies
performed in vivo demonstrated that miR-141 and miR-429 may
act as tumor suppressor genes in this disease.
RESULTS
Expression of miR-200 and Selected Genes Involved in the EMT
in a Cohort of Pancreatic Tumors
We first assessed by quantitative real-time PCR the expression levels of
selected mRNAs and miRNAs involved in EMT in a cohort of 31 pri-
mary pancreatic tumors with matching adjacent macroscopically
normal parenchyma that was selected 1–3 cm distal from the macro-
scopic tumor margin. We found that miR-200a (14/31 tumors [45%],
p = 0.03), miR-429 (19/31 tumors [61%], p = 0.001), and miR-205
(20/31 tumors [65%], p = 0.0001) are overexpressed in PDAC primary
tumors compared with adjacent normal tissues (Figure 1A; Table 1;
Tables S1 and S2). We further analyzed the expression levels of miR-
200a, miR-141, and miR-429 in nine paired microdissected ductal
and stroma samples to better address the cell compartment of origin
for these miRNAs because these miRNAs were constantly detected, at
least in samples from ductal origin. The results presented in Figure 1B
demonstrate thatmiRNAsare overexpressed inductal cells as compared
with the stromal compartment of pancreatic tumors (**p < 0.01). Spe-
cifically,miR-200a expression is detectable in 9 out of 10 ductal samples
(90%), but in only 3 out of 9 (33%) in the corresponding stromal
compartment, while miR-141 is detected in all ductal samples but in
only 4 out of 9 (44%) of the paired stromal components. Lastly, miR-
429 is expressed in 7 out of 9 (78%) ductal cells and in 3 out of 9
(33%) of corresponding stroma (Figure 2B;Table S3).Collectively, these
results indicate that epithelial cancer cells are likely the main source for
the candidate miRNAs expression in PDAC tumors.
We next addressed the expression of selected genes governing EMT in
the same cohort of samples. We found that CDH1mRNA expression
is significantly decreased in PDAC tissues as compared with normal
adjacent parenchyma (Figure 1A). CDH1 levels are low in 11 of 31
primary tumors (range = 0.16–0.49, p = 0.0001; Table 1; Table S1),
suggesting that EMT is frequent in this cohort of PDAC samples.
Only two tumors (6.5%) demonstrate CDH1 overexpression as
compared with normal parenchyma (Table 1; Tables S1 and S2).
On the other hand, ZEB1 and ZEB2mRNA levels remain unchanged
between tumor and normal tissues (Figure 1), although variability is
high among samples (Table 1; Table S1).
Table 1. Expression Levels of Members of the miR-200 Family and ZEB1, ZEB2, or CDH1 in PDAC Tumors as Compared with Adjacent Normal Tissue
miR-200a miR-200b miR-429 miR-200c miR-141 miR-205 ZEB1 ZEB2 CDH1
Overexpressiona 14/31, 45% 9/31, 29% 19/31, 61% 9/31, 29% 8/31, 26% 20/31, 65% 13/31, 42% 5/31, 16% 2/31, 6.5%
Underexpressiona 7/31, 23% 4/31, 13% 5/31, 16% 12/31, 39% 5/31, 16% 6/31, 19% 9/31, 29% 9/31, 29% 11/31, 35.5%
Unchangeda 10/31, 32% 18/31, 58% 7/31, 23% 10/31, 32% 18/31, 58% 5/31, 16% 9/31, 29% 17/31, 55% 18/31, 58%
Ct values (range): normal tissue 23–32 25–33 31–36 21–29 24–32 26–37 27–40 27–36 24–28
Ct values (range): tumoral tissue 22–30 25–30 30–34 21–26 23–29 26–37 27–40 27–35 24.3–28
Fold change (2DDCt) > 2: overexpression; fold change (2DDCt) < 0.5: underexpression.aThe proportion of tumors overexpressing (FC > 2) and underexpressing (FC < 0.5) the target
gene is shown as a percentage.
www.moleculartherapy.orgAs stated before, the miR-200 family members repress EMT, the initi-
ating step of metastasis, by maintaining the epithelial phenotype
through direct targeting of ZEB1 and ZEB2, the well-characterized
transcriptional repressors of CDH1. Consequently, we investigated
whether the levels of miR-200 family members correlated with
ZEB1, ZEB2, or CDH1 expression in this cohort of patients. We found
a significant positive correlation between miRNAs from the miR-200
family and CDH1 expression levels (Table 2). On the other hand, no
correlation exists between miR-205 and CDH1 expression levels. As
for ZEB1, we identified a negative correlation with miR-200a, miR-
200c, miR-141, and miR-205 expression in these samples. Finally, a
negative correlation between ZEB2 and miR-200c, miR-429, and
miR-205 was also demonstrated. These results suggest that miR-200
family members target ZEB1 and ZEB2, and restrain EMT in this
cohort of PDAC samples. We next address whether DNA methyl-
ation could also account for EMT-related gene expression in these
samples. CDH1 promoter hypermethylation was not detected in these
samples, whereas half of tumors (4/11) demonstrated, albeit low,
methylation levels of ZEB1 and ZEB2 promoters (Table 3). However,
no correlation was found between ZEB1 or ZEB2 expression levels
and DNA promoter methylation (data not shown). Thus, our results
strongly suggest that ZEB1 and ZEB2 expression are mainly
controlled by miRNA in these samples.
Development of a Mouse Cohort of PDAC PDXs
To gain further insights into the expression and the role of miR-200
family members and ZEB1, ZEB2, and CDH1 in EMT in PDAC, we
generated a collection of PDXs from a cohort of 32 patients who un-
derwent surgery for PDAC. An expert pathologist selected the tumor
fragments to be implanted from the invading front of the tumor.
Eighteen of the 32 tumors were successfully perpetuated (56%), 11
of which were used in the present study. The histological analysis con-
firms the remarkable histological similarities between primary tumors
and corresponding PDX (Figure 2A). Hematoxylin, eosin, and
hyaluronic acid staining analysis performed by an expert pathologist
reveals that tumor cellularity is seemingly higher in PDXs than in pri-
mary tumors, although some degree of heterogeneity is observed. Low
(0%–6%) and moderate (10%–18%) stroma levels were measured in 2
out of 11 and 9 out of 11 PDXs, respectively (Figure 2B; Table S3), re-
flecting the well-characterized deprivation of the stromal component
following serial passaging in mice.30 We next analyzed the genetic
landscape of primary PDAC tumors and corresponding PDXs. Wefound that the proportion and the combination of genetic aberrations
measured in PDAC primary tumors is perfectly mirrored by PDXs
(Table 4) and is in agreement with previous reports from the
literature.2 The latter demonstrates that no significant loss or accu-
mulation of the analyzed driver genetic alterations occurred during
passaging of PDXs. Taken together, we consider that the PDXs
used in this study are a bona fide model of human pancreatic tumors.
Because of the paucity of paired human primary tumor and metas-
tasis available for research, we used this collection of orthotopic
PDXs to generate a paired library of 25 experimental metastases.
Similar to what was observed during PDX perpetuation, no additional
genetic alterations were found in the metastases (Table 4).
Expression of miR-200 Family Members and ZEB1, ZEB2, and
CDH1 in PDX and Experimental Metastases
Next, we used this model system to better understand the pattern of
expression and the impact of miR-200 family members in the regula-
tion of the epithelial state of pancreatic tumors, and the expression of
ZEB1/ZEB2 epithelial gene transcriptional repressors in vivo. We first
investigated whether the expression of these candidate genes was
altered following PDX propagation and distal dissemination. For
this purpose, 22 independent samples from 11 original PDXs were
analyzed with paired primary tumors. Also, 25 paired experimental
metastases were studied. Two of the five miRNAs analyzed, miR-
200a (2.93-fold increase) and miR-200c (14-fold increase), were over-
expressed in PDXs when compared with primary tumors (p = 0.017
and p = 0.0001, respectively, Kruskal-Wallis and Tukey’s honestly sig-
nificant tests; Figures 3A and 3C). On the other hand, ZEB2 expres-
sion levels were decreased in PDXs as compared with primary tumors
(p = 0.019; Figure 3G), whereas ZEB1 and CDH1 RNA levels re-
mained unchanged (Figures 3F and 3H). No correlation was found
between the expression levels of candidate miRNAs, EMT effectors,
and KRAS, EGFR, CDKN2A, TP53, and SMAD4 status (data not
shown). Notably, the RNA levels of all target miRNAs and EMT reg-
ulators remained stable during PDX dissemination inmice, regardless
of the site of metastasis (Figures 3A–3H).
Role of miR-200 Family Members in Experimental Models
of PDAC
Our next goal was to address the functional significance of the expres-
sion of the miR-200 family members in experimental models of
PDAC. Using quantitative real-time PCR, we first characterized theMolecular Therapy: Nucleic Acids Vol. 17 September 2019 493
Figure 2. Characterization of the Patient-Derived Xenografts (PDXs) Used in
This Study
(A) Cases TP16, TP17, and TP26 are shown. H&E staining of normal tissue (sub-
panels A, D, and G), paired tumor tissue (subpanels B, E, and H), and corresponding
PDXs (subpanels C, F and I). All images are original magnification 100. (B) Hyal-
uronic acid staining of orthotopic PDXs is shown as a surrogate marker of des-
moplastic reaction (left: PDX TP7; right: PDX TP19).
Molecular Therapy: Nucleic Acidsexpression levels of the candidate miRNAs in a panel of human
PDAC-derived cell lines that recapitulate the molecular heterogeneity
of these tumors. We selected PANC-1 cells because these cells: (1) ex-
press low levels of miR-200 family members; and (2) show no evi-
dence of promoter methylation of CDH1, ZEB1, and ZEB2 genes
(data not shown).31 Thus, PANC-1 cells were selected for functional
studies and were transduced with lentiviral vectors encoding for miR-
200 family members, alone or in combination, as reported before.32
By quantitative real-time PCR, we found that transduced cells readily
overexpressed miR-200 clusters (miR-200b-a-429 and miR-200c-
141) or individual miRNAs (miR-141 and miR-429), and to a lesser
extent miR-200c, in cells transduced with the miR-200c-141 cluster
(Table S4). Robust and reproducible expression of the candidate
miRNAs was also detected following transduction of other PDAC
cell lines (data not shown).
We next investigated the functional consequences of the overexpres-
sion of candidate miRNAs in experimental models of PDAC.
PANC-1 cells transduced with a lentiviral vector encoding for GFP
were used as a control (PANC-1-GFP). We found that PANC-1 cell494 Molecular Therapy: Nucleic Acids Vol. 17 September 2019proliferation remained largely unchanged following expression of
candidate miRNAs, as compared with control-transduced cells (Fig-
ure 4A). On the other hand, overexpressing miR-429 strongly
impaired PANC-1 cell 3D growth and migration. Indeed, spheroids
from PANC-1 cells expressing miR-429 were significantly smaller
as compared with control spheroids after 6 days in culture (2.23 ±
0.28-fold reduction; p < 0.001, two-way ANOVA test; Figure 4C).
Interestingly, real-time imaging using IncuCyte Zoom revealed that
miR-429 not only rapidly diminished the size of spheroids, but also
strongly impacted cell viability because we evidenced an increase of
dying cells after 60 h in culture (Figures 4B and 4D) that were easily
distinguishable from GFP-positive, healthy cells. miR-429 expression
also has a profound inhibitory effect on PDAC cell migration. Real-
time imaging of gap-closure assay indicated that control PANC-1
cells migrate with high efficacy into the wound region (Figure 4E).
Complete wound closure was achieved after 12 h (Figures 4E and
4G). On the other hand, expressing miR-429 strongly inhibited
the gap-closure activity of PANC-1 cells (1.6 ± 0.4-fold reduction,
p < 0.001, two-way ANOVA test; Figures 4F and 4G), and
PANC-1-miR-429 cells failed to complete wound closure. These
data indicate that miR-429 strongly inhibits the migration of PDAC
cells. Molecular examination of PANC-1 cells indicated that overex-
pression of miR-429 decreases ZEB1, N-cadherin, and Vimentin
expression, whereas E-cadherin expression was upregulated (Fig-
ure 4G). Thus, miR-429 induces a mesenchymal-to-epithelial
(MTE) switch that is associated with inhibition of 3D tumor growth
and migratory capacities of PDAC cells.
We next engrafted candidate miRNA-expressing cells that were in the
pancreas of nudemice to address the tumorigenic potential of miRNA
from the miR-200 family. No macroscopic histological differences
were observed among the orthotopic tumors (Figures 5A–5F) or
the metastases (Figures 5G–5L) generated from the control of
miRNA-expressing cells, respectively. Figures 6A and 6B are repre-
sentative of orthotopic and metastatic tumor growth, respectively.
miR-200c-141 and miR-200b-a-429 miRNA clusters failed to inhibit
pancreatic tumor growth, as compared with GFP-expressing PANC-1
cells; indeed 100% (13/13) and 92% (12/13) of mice engrafted with
PANC-1/miR-200c-141 and PANC-1/miR-200b-a-429 developed or-
thotopic PDAC tumors, respectively, as compared with control cells
(85% tumor formation, 11/13; Figure 6C). The proportion of mice en-
grafted with PANC-1 cells expressing either miRNA cluster displays a
similar incidence of distal metastases (7/13, 53%) as compared with
control tumors (5/13, 30%; Figure 6C). On the other hand, overex-
pression of miR-429, and to a lesser extent of miR-141, in PANC-1
cells strongly inhibits pancreatic carcinogenesis because 30% (4/13)
and 54% (7/13) of mice receiving these cells developed tumors,
respectively (Figure 6C). Furthermore, expressing miR-429 signifi-
cantly inhibited PDAC tumor dissemination (1/13, 8%, p < 0.05; Fig-
ure 6C). Along the same line, the median tumor volume at sacrifice
was also strongly decreased only in miR-429, and again to a lesser
extent in miR-141-expressing tumors, as compared with control (Fig-
ure 6D). Tumors collected at the completion of the experiment
demonstrated increased levels of the corresponding miRNAs as
Table 2. Gene Expression Correlation between miR-200 Family Members




p = 0.038a p = 0.019a p = 0.017a
miR-200b
0.263 0.333 0.642
p = 0.151 p = 0.067 p = 0.0001a
miR-200c
0.460 0.298 0.580
p = 0.009a p = 0.102 p = 0.0007a
miR-141
0.41 0.375 0.610
p = 0.021a p = 0.038a p = 0.0003a
miR-429
0.2512 0.227 0.368
p = 0.170 p = 0.218 p = 0.041a
miR-205
0.374 0.2088 0.298
p = 0.038a p = 0.208 p = 0.102
Gene expression is calculated using the 2DCt formula as described before. Correlation
coefficient values were assessed by Spearman analysis.aSignificant p values, p < 0.05.
www.moleculartherapy.orgcompared with control (Figures 6E and 6F). In addition, we found
that CDH1 levels were significantly increased in the miR-429 trans-
duced group (Figure 6I). We also identified a trend indicating that
ZEB1 and ZEB2 expression are downregulated in miR-141- and
miR-429-expressing tumors, which failed short to reach statistical sig-
nificance because of the low tumor burden in these experimental
groups (Figures 6G and 6H). Taken together, our results demonstrate
that miR-429, and to a lesser degree miR-141, decreases PDAC tumor
growth and metastatic spread, and modulates the level of expression
of key regulators of EMT.
DISCUSSION
ThemiR-200 familymembers (miR-200a, miR-200b, miR-200c, miR-
141, and miR-429) and miR-205 are commonly associated with
EMT,11 a fundamental process in the early steps of the metastatic
dissemination. The canonical hypothesis states that the miR-200 fam-
ily inhibits the EMT process through the targeted silencing of ZEB
proteins, resulting in increased CDH1 expression and the acquisition
of a more differentiated epithelial phenotype.18,33 Despite the impor-
tance of this process in PDAC carcinogenesis, the status of expression
of miR-200 family members has been insufficiently investigated to
date. In this work, we found that miR-200a, miR-429, and miR-205
are frequent in PDAC tissue samples when compared with match-
paired normal parenchyma. Most tumors analyzed (84%) overexpress
at least one of the candidate miRNAs, whereas a significant propor-
tion (45%) express three or more. Importantly, the current work sug-
gests that most of the miRNAs detected within PDAC tumors can be
attributed to epithelial cancer cells, rather than the stromal compart-
ment. In previous reports, miR-205 overexpression in PDAC has been
observed in a limited set of cases,34 whereas miR-429 and miR-200a
overexpression have been reported in metastatic PDAC cell line
models.18,25 Also, miR-200b overexpression has been described forcell lines and biopsies.35 In contrast, Dhayat et al.36 described the
decreased expression of members of the miR-200 family in PDAC tu-
mors. This result, however, must be interpreted with caution because
the authors used a normal pancreas from benign, non-inflammatory
pancreatic specimens as the control in their study, instead of paired
adjacent normal parenchyma. Lastly, miRNAs that are organized in
clusters, such as miR-11 and miR-998, usually share a co-dependent
expression pattern.37 Interestingly, in our sample cohort, miR-200c
and miR-141, and miR-200b, miR-200a, and miR-429, share the
same expression pattern in only one-third of the tumors, regardless
of RNA quality status, technical deviations, or genetic abnormalities.
This later finding strongly suggests that miRNAs from the miR-200
family may differ in stability and/or post-transcriptional processing
in PDAC tumors.
We demonstrate herein that downexpression of CDH1, a bona fide
marker of EMT, is a frequent event in PDAC tumors as compared
with matching normal parenchyma. In contrast, expression of
ZEB1 and ZEB2 is low and unchanged in most paired samples
analyzed during this study (58%), confirming previous findings
from the literature.38 During this study, promoter methylation of
CDH1, ZEB1, and ZEB2 genes was detected in only 40% of samples.
This finding partly contradicts previous work reporting ZEB2 pro-
moter methylation in 90% of PDAC samples.31 Such discrepancy
can be easily explained by differences in the methods used, and advo-
cate for alternative expression silencing modalities for these genes.
Indeed, several studies demonstrated that CDH1 expression can be
directly regulated by ZEB1 and ZEB2.5,29 Furthermore, ZEB1 sup-
presses the transcription of miR-200 family members, in particular
the expression of miR-141 and miR-200c.28 During this study, we
confirmed these findings because we measured a negative correlation
between the expression levels of ZEB1 and ZEB2 and the miR-200
family, and a positive regulation between miR-200 and the expression
levels of CDH1 in primary PDAC tumors. Altogether, our results
further suggest that miR-200 family members actively participate to
maintain the epithelial state of a proportion of pancreatic tumors
by suppressing ZEB1 and ZEB2, two well-described transcriptional
repressors of CDH1.
Orthotopic PDXs provide a library of tumors that not only reflects the
spectrum of primary tumors in the clinical setting, but also partially
reproduces their dissemination propensity.39,40 This preclinical
model maintains key genetic aberrations present in primary tumors,
although the expression levels of other key molecules may differ.41
During this study, we confirmed that PDXs perfectly mirror the ge-
netic alterations found in primary tumors. On the other hand, we
found that miR-200a and miR-200c levels were higher in orthotopic
xenografts as compared with primary tumors, whereas ZEB2 pre-
sented significantly lower levels. This latter finding can be explained
by the increase in tumor cellularity in PDX caused by the progressive
loss of human stroma during passage inmouse, because we found that
epithelial tumor cells mostly express the candidate miRNAs detected
in primary tumors. Using this PDAC PDX cohort, we were able to
compare gene expression patterns not only in primary tumors avatarsMolecular Therapy: Nucleic Acids Vol. 17 September 2019 495
Table 3. Expression and Promoter Methylation of ZEB1 and ZEB2 in PDAC
ZEB1 ZEB2
Tumor Sample 2DCT Methylation 2DCT Methylation
TP1 8.33 M* 8.6 U
TP5 ND U ND M
TP7 ND U ND U
TP9 11.055 U 11.4 U
TP10 12.06 U 10 U
TP11 11.86 U 11.9 U
TP16 7.60 M* 7.5 U
TP18 11.96 M* 10.4 U
TP19 ND M* ND M*
TP26 12.31 U 9.5 M*
TP32 9.64 U 9.2 M*
Gene expression analyzed by quantitative real-time PCR is expressed as 2DCt versus
normal adjacent tissue. M, methylated; M*, low intensity of the methylation signal;
ND, not determined; U, unmethylated.
Molecular Therapy: Nucleic Acidsbut also during metastatic dissemination, a setting out of reach in
clinical studies. We found that the levels of CDH1, ZEBs, and mem-
bers of the miR-200 family remained unchanged in the 47 experi-
mental metastases tested when compared with the corresponding
orthotopically implanted PDXs. Although EMT is expected to play
a role in tumor invasion and metastases formation,42 bulk analysis
of metastatic material failed to highlight changes in expression of
EMT regulators during this study. However, these results were
obtained from late-stage metastasis; future works should address
miRNAs and ZEB expression in early disseminated cancer cells.
Considering the high heterogeneity of PDAC tissues,43 further studies
based on single-cell analysis may help better understand the molecu-
lar processes underlying early and late distal dissemination events in
these tumors.
We next addressed the functional consequences of overexpressing
members from the miR-200 family into pancreatic cancer cell lines.
We selected PANC-1 cells in which EMT gene regulators gene expres-
sion is not controlled by DNA methylation. We found that miRNA
overexpression did not significantly impact cancer cell proliferation
(data not shown). Molecular investigations revealed that miR-429 re-
verses EMT in PDAC-derived cell lines. Notably, our work is in agree-
ment with recently published data showing that ZEB1 is a direct target
of miR-429,10 and that ZEB targeting provokes a molecular cascade
inducing mesenchymal-to-epithelial transition of PDAC cells. This
results in smaller and denser spheroids with poor viability and in
strong inhibition of cell migration. The functional importance of
miR-429 was further validated in vivo, because this miRNA was the
most effective to decrease tumor occurrence, tumor size, and metasta-
tic spread. This latter effect is associated with an increase of CDH1
expression and a decrease of ZEB1 and ZEB2 expression, a pattern
that was confirmed in vitro. Notably, miR-429 expression within
the miR-200a-b cluster failed to inhibit tumor growth. To date, we496 Molecular Therapy: Nucleic Acids Vol. 17 September 2019do not have clear explanations for this discrepancy; in transduced
cells, miR-429 expression levels are similar, whether expressed alone
or as part of a cluster. Further studies are needed to determine
whether miR-200a and miR-200b may counteract miR-429 antitu-
moral activity in PDAC experimental tumors. However, our results
are in agreement with results from the literature describing miR-
429, but also miR-141, as tumor suppressors in papillary thyroid
cancer20 and PDAC27 and in gastric cancer,23 respectively. The inter-
pretation of these observations is challenging because miR-429 and
miR-141 are frequently overexpressed in primary tumors. Two poten-
tial explanations emerge: (1) a transient deregulation of miR-429 or
miR-141 exclusively occurs during the early stages of tumorigenesis,
and (2) the cellular context may significantly impact in the functional
role of miRNAs including miR-429 and miR-141.11,44 Further work is
needed to determine whether delivering miR-429 in established tu-
mors using either viral vectors45 or exosomes46 may impede experi-
mental PDAC tumor growth. In conclusion, we demonstrated during
this work that the miR-200 miRNA family is overexpressed in a
comprehensive biological cohort of PDAC, and that members from
this family, and especially miR-429, may have significant impact as
nucleic acid-based therapies for this disease.
MATERIALS AND METHODS
Tumor Biopsies
Tumor tissues and normal adjacent pancreatic parenchyma were
collected from 48 patients undergoing surgical resection for PDAC
between 2003 and 2011 at the Bellvitge Hospital, Barcelona, Spain.
The study was approved by the Ethical Committee of University Hos-
pital of Bellvitge CEIC 02/04, and written informed consent was
obtained from all patients for the use of their tissues for research
purposes.
Animals Studies
Six-week-old male nude Harlan mice weighing 18–22 g were used for
tumor perpetuation. Animals were housed in cages with autoclaved
bedding, food, and water in a sterile environment. Mice were main-
tained on a daily 12-h light, 12-h dark cycle. All experiments with
mice were approved by the IDIBELL Animal Care and Use Commit-
tee (CEEA4591).
PDXs Cohort
Fresh surgical fragments of PDAC were minced into small fragments
of 2 mm3 in size, and macroscopically viable tumor tissue fragments
were implanted in the body tail of the pancreas (orthotopic implan-
tation [OT]) of two animals per tumor under anesthesia with isoflur-
ane. Meloxicam was administered subcutaneously just before and 24
and 48 h after surgery, to avoid themice suffering. After implantation,
tumor formation was monitored weekly by palpation. The first tumor
passage was performed when an intra-abdominal mass measuring
approximately 1 cm in diameter was palpated. The mice were anes-
thetized and euthanized by exsanguination with cardiac puncture
and ulterior pneumothorax. Successive OT passages were performed
in two animals until the fifth passage when the tumor was considered
perpetuated.
Table 4. Growth and Dissemination Patterns of Pancreatic PDXs and Genetic Characterization of Xenograft Samples (Orthotopic and Corresponding Metastases)
PDX TP1 PDX TP5 PDX TP7 PDX TP9 PDX TP10 PDX TP11 PDX TP16 PDX TP18 PDX TP19 PDX TP26 PDX TP32
Timea 4.5 2.5–3 3 2.5 1–1.5 2.75 4 8.5 2.5–3 2 8
Differentiationb mod mod poor poor poor poor poor poor mod poor mod
Local invasion yes yes yes yes yes yes yes yes yes yes yes
Metastasis
Peritoneal          
Lymph node       
























BRAF WT WT WT WT WT WT WT WT WT WT WT
PI3KCA WT WT WT WT WT WT WT WT WT WT WT






































amp, amplification; del, deletion; mod, moderate; WT, wild type.aTime elapsed between passages (months).


























































Figure 3. Expression Levels in PDX Model
(A–H) Expression levels (2DCt) of miR-200 family members
(A, miR-200; B, miR-2006b; C, miR-200c; D, miR-141; E,
miR-429) and ZEB1 (F), ZEB2 (G), and CDH1 (H) in 11 primary
tumors (PT) paired with PDXs and corresponding metastases
(M1) (the p value calculated with Tukey multiple comparisons
of means compares the mean of each group in pairs was
shown).
Molecular Therapy: Nucleic AcidsLaser Capture Microdissection
Laser capture microdissection (LCM) of tumor cells and corre-
sponding stroma was performed with the Applied Biosystems Arc-
turusXT LCM System, using Arcturus polyethylene naphthalate
(PEN) Membrane Glass slides (Applied Biosystems, Life Technolo-
gies, UK) following staining with free RNase H&E. An average of
8,00,000–10,00,000 mm2 of tumor cells and stroma surface were
separately captured and immediately frozen at 80C prior to sub-
sequent manipulation.498 Molecular Therapy: Nucleic Acids Vol. 17 September 2019Molecular Characterization of Tumor Samples
Genetic aberrations in the KRAS, p16/CDKN2A,
TP53, SMAD4, EGFR, BRAF, and PI3KCA genes
were assessed using a variety of techniques
including PCR and Sanger sequencing (TP53,
PI3KCA, and CDKN2A), RT-PCR and Sanger
sequencing (SMAD4 and EGFR), restriction
fragment length polymorphism (RFLP)-PCR
(KRAS),30 and single-nucleotide primer extension
(SNuPE) (BRAF).31 Epidermal growth factor recep-
tor (EGFR) copy number was determined by
fluorescence in situ hybridization (FISH). The
methylation status of the promoters of CDH1,
ZEB1, and ZEB2 was studied by methylation-spe-
cific melting curve analysis (MS-MCA) as
described previously.30 A different test to assess
the methylation status had been described,17,32,33
but not withMS-MCA; for this reason, we designed
specific primers.
Cell Lines
Pancreatic cancer-derived cell line PANC-1 was
obtained from ATCC LGC Standards (Molsheim,
France) and grown in DMEM containing +1 g/L
glucose (Invitrogen, Carlsbad, CA, USA). The
HEK293FT cell line used for production of the
vectors was obtained from Invitrogen (Carlsbad,
CA, USA) and maintained in DMEM containing
4.5 g/L glucose (Invitrogen, Carlsbad, CA, USA).
All media were supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 U/mL peni-
cillin, and 100 mg/mL streptomycin (complete
medium) (all reagents were from Invitrogen).
Cell lines were grown in a humidified incubator
at 37C in 5% CO2 and kept free from myco-plasma contamination using plasmocin (InvivoGen, Toulouse,
France).
Lentiviral Vectors Production and Titration
The plasmids pLenti 4.1 Ex, pLenti 4.1 Ex miR-200c-141, and
pLenti4.1 Ex miR-200b-a-429 co-expressing the indicated
miRNA clusters and puromycin were a kind gift of P.A. Gregory
and G.J. Goodall.12 Lentiviral backbones encoding for miR-141 or
miR-429 precursors were purchased from System Biosciences
Figure 4. miR-429 Expression Inhibits 3D Growth and
Migration, and Inhibits EMT of PDAC Cells
PANC-1 cells were transduced by lentiviral vectors en-
coding for miR-429, as described in the Materials and
Methods. As a control, PANC-1 cells were transduced with
vectors encoding for GFP. (A) Cell confluence was
measured using the IncuCyte Zoom. Results are mean ±
SD of triplicates from two independent sets of transduction.
(B) Description of the surface of spheroids and dead cells
used for the analysis. (C) Representative images of
spheroid formation using control of miR-429-expressing
PANC-1 cells, at the time indicated, using the IncuCyte
Zoom. (D) Quantification of spheroid surface and cell death
in real-time using the IncuCyte Zoom. Results are mean ±
SD of triplicates from two sets of transduction. ***p < 0.001.
Cells were seeded in 96-well ImageLock plate, and ho-
mogeneous scratch wounds were performed using the
WoundMaker mechanical device from Essen BioScience
(Sartorius) 24 h later. (E) Representative wound closure in
control (top) and miR-429-expressing (bottom) PANC-1
cells at the time indicated. Red area: mask used to calcu-
late the relative wound density, as a measure (%) of the
density of the wound region relative to the density of the cell
region. (F) Real-time quantification of wound closure in both
groups using the IncuCyte Zoom. Results are mean ± SD of
quadruplicates from two sets of transduction. ***p < 0.001.
(G) Western blotting for ZEB1, N-cadherin, Vimentin, and
E-cadherin in PANC-1 cells expressing or not miR-429.
b-Actin was used as a loading control. Molecular weights
(in kDa) are indicated on the left side. Results are repre-
sentative of two different sets of transduction.
www.moleculartherapy.org(Palo Alto, CA). All vectors co-expressed GFP (plasmids pLenti 4.1
Ex EGFP and Lentiviral backbones copGFP). The lentiviral vectors
were generated using the Lenti-SmartINT kit (InvivoGen, Toulouse,Molecular TheraFrance) following the manufacturer’s instruc-
tions in a BSL-3 facility (Technology cluster;
INSERM U1037, Toulouse, France). In brief,
the lentiviral plasmid and the LENTI-Smart re-
agents were complexed and then added onto the
293FT cells following the manufacturer’s recom-
mendations. Medium was changed 24 h later,
and cell-free supernatant was collected 48 h
after transfection. The supernatants were filtered
using a 0.45-mm polyvinylidene fluoride (PVDF)
filter, treated by DNase (Invitrogen), aliquoted,
and stored at 80C until use. Lentiviral vectors
were titered by flow cytometry for GFP-positive
cells (fluorescence-activated cell sorting [FACS])
and by ELISA for p24 (Innogenetics, Ghent,
Belgium).
Cell Transduction with Lentiviral Vectors
One day before transduction, a total of 5  104
cells were cultured in 48-well plates in 500 mL
of complete medium. Cells were transducedwith 1,000 ng/mL p24 in the presence of protamine sulfate
(4 mg/mL), in 250 mL of transduction medium (Quantum 263;
PAA) overnight. A total of 5 mg/mL puromycin was added 48 h laterpy: Nucleic Acids Vol. 17 September 2019 499
Figure 5. Experimental Tumors Generated fromPDAC
Cell Lines Expressing Candidate miRNAs from the
miR-200 Family
Panc-1 cells were transduced with lentiviral vectors en-
coding for GFP (A, D, G, and J), miR-200a-b-429 (B and H),
miR-200c-141 (C and I), miR-141 (E and K), or miR-429
(F and L) and implanted in the pancreas of athymic mice as
described in the Materials and Methods. Mice were sacri-
ficed, and tumors were sampled and stained using H&E.
(A–F) Primary tumors. (G–L) Metastatic growth. Results are
representative of 13 mice per group.
Molecular Therapy: Nucleic Acids(InvivoGen, Toulouse, France). Transduction efficiency was
measured by FACS analysis.
RNA Isolation and Quantification
Total RNA from cell lines was isolated by the TRIzol method (TRIzol
Reagent; Invitrogen, Carlsbad, CA, USA) or using the miRCURY
RNA isolation kit (Exiqon, Vedbaek, Denmark) for primary tumors,
according to the manufacturer’s instructions. RNA concentration was
measured with ND-1000 NanoDrop spectrophotometer (Thermo
Scientific). For laser microdissected samples, RNA was isolated with
the Arcturus PicoPure RNA isolation Kit (Applied Biosystems, Life
Technologies, UK). miRNAs and target genes expression were quan-
tified using 1 mg or 500 ng of total RNA extracted from cell lines or
primary tumors, respectively. The entire RNA eluate from laser cap-
ture-microdissected samples was used for reverse transcription.
Simultaneous reverse transcription of mRNA and miRNA was per-
formed using the miScript PCR System (QIAGEN, Cortaboeuf,
France) following the manufacturer’s recommendations. qPCR was
carried out using SYBRGreen PCR Master Mix (QIAGEN, Corta-
boeuf, France). cDNAs were analyzed in triplicate using a StepOne-
PlusReal-Time PCR System (Life Technologies, Carlsbad, CA,500 Molecular Therapy: Nucleic Acids Vol. 17 September 2019USA). Expression levels were calculated using
the DCt (cycle threshold) formula. RNU48 and
human actin were used as standard for miRNAs
and target genes, respectively. The expression
levels relative to control (paired normal tissue,
control-transduced cell line), expressed as fold
change (FC), were calculated using the formula
2DDCt.34 Infra-expression was defined as a FC
value <0.5, whereas overexpression was achieved
when FC > 2 (see Table S1 for qPCR primer
sequences).
Western Blotting
Proteins were extracted from PANC-1 trans-
duced cells, resolved on 6%–12% gradient
SDS-polyacrylamide gels (50 mg/lane), and
transferred to nitrocellulose membrane. After
room-temperature blocking for 1 h, blots were
incubated overnight at 4C with antibodies
against a panel of genes involved in EMT,following the manufacturer’s instructions (panel #9782; Cell
Signaling Technology). b-Actin (clone C4; Santa Cruz) was used
at a dilution of 1:2,000. Secondary HRP-conjugated antibodies (dilu-
tion 1:20,000; Bio-Rad) were added, and blots were incubated for
1 h at room temperature. Following several washes, immunoreactive
proteins were visualized using Clarity ECL (Bio-Rad) and imaged
with ChemiDoc XRS+ (Bio-Rad).
Real-Time Migration Analysis
A total of 35,000 PANC-1 cells overexpressing miR-429 were seeded
in 100 mL of complete medium in a 96-well ImageLock plate (Essen
BioScience, Sartorius). PANC-1-expressing GFPs were used as con-
trol. Twenty-hours later, homogeneous scratch wounds were per-
formed using the WoundMaker mechanical device from Essen
BioScience (Sartorius). Pictures of the scratch wound were taken
every hour for 36 h using the IncuCyte Zoom (Essen BioScience,
Sartorius) to assess cell morphology at every time point. A mask
was applied to each picture to determine the relative wound density,
as a measure (%) of the density of the wound region relative to
the density of the cell region, according to the manufacturer’s
instruction.
(legend on next page)
www.moleculartherapy.org
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Molecular Therapy: Nucleic AcidsReal-Time Cell Proliferation and Spheroid Formation Analysis
A total of 10,000 or 25,000 PANC-1 cells overexpressing miR-429
were seeded in 100 mL of complete medium in 96-well plates or in
Nunclon Sphera 96 U-well plates (Thermo Fisher Scientific) for cell
proliferation and spheroid formation analysis, respectively. PANC-
1-expressing GFPs were used as control. Pictures were taken at the
time indicated using the IncuCyte Zoom (Essen BioScience, Sarto-
rius). A mask was applied to each picture to determine the surface
of live cells (GFP fluorescence) and cell debris.
In Vivo Tumorigenicity Assay
For orthotopic injection, a total of 5 106 transduced or control cells
were injected in the body tail of the pancreas under anesthesia with
isoflurane. Thirteen mice were used for each group. After injection,
tumor formation was checked weekly by palpation. Mice were sacri-
ficed after 3 months of implantation or if endpoint criteria were met,
and tumor volume was calculated as previously described.45
Statistical Analysis
To compare the expression level of members of the miR-200 family
and their target genes in paired primary tumor-adjacent nontumoral
tissue, we used the Wilcoxon test (p < 0.05 was considered signifi-
cant). The correlation between miRNAs and target genes expression
was carried out by Spearman analysis (significant when p < 0.05). To
compare the distributions (2DCt) between primary tumor, adjacent
normal tissue, orthotopic tumor, and metastasis for each miRNA
and target genes, we used the Kruskal-Wallis test, considering differ-
ences when p < 0.05. Then, the Tukey multiple comparisons of means
were applied for pairwise comparisons if significant differences were
previously evidenced. For differences in the ability to generate tumors
and metastases, contingency tables and chi-square test were utilized.
Differences in tumor volume in the orthotopic in vivo experiment
were analyzed using the Kruskal-Wallis and the Benjamini and Hoch-
berg tests.
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